Dosing & Uses
AdultPediatric
CHAPLE Syndrome
Pending FDA approval for treatment of DC55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (CHAPLE) syndrome
CHAPLE Syndrome
Pending FDA approval for treatment of DC55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (CHAPLE) syndrome
Next:
Pharmacology
Mechanism of Action
Monoclonal blocking antibody to complement protein C5
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
